1
Views
3
CrossRef citations to date
0
Altmetric
Original Article

Neuroleptic Malignant Syndrome Associated with Clozapine Treatment

, , &
Pages 91-95 | Published online: 04 Dec 2011

REFERENCES

  • Levenson JL: Neuroleptic malignant sydrome. Am J Psychia-try 1985; 142:1137–1145
  • Tesar GT: Neuroleptic malignant syndrome; An update. Probl Crit Care 1988; 2:149–158
  • Mann SC, Caroff SN, Lazarus A: Pathogenesis of the neuroleptic malignant syndrome. Psychiatry Ann 1991; 2:175–180
  • Weller M, Kornhuber J: Does clozapine cause neuroleptic malignant syndrome? J Clin Psychiatry 1991; 54:70–71
  • Burrell MF, Fewster C: Clozapine-treated NMS. Br J Psychia-try 1991; 158:569–578
  • Goates MG: An apparent neuroleptic malignant syndrome without extrapyramidal symptoms upon initiation of clozapine therapy: Report of a case and results of a clozapine rechal-lenge. J Clin Psychopharmacol 1992; 12:139–140
  • Miller DD, Sharafuddin MJA, Kathol RG: A case of clozap-ine-induced neuroleptic malignant syndrome. J Clin Psychia-try 1991; 52:99–101
  • DasGupta K, Young A: Clozapine-induced neuroleptic malig-nant syndrome. J Clin Psychiatry 1991; 52:105–107
  • Pope HG, Cole JO, Choras PT, Fulwiler CE: Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 1986; 174:493–495
  • Nemecek D, Rastogi-Cruz D, Csernansky JG: Atropinism may precipitate neuroleptic malignant syndrome during treat-ment with clozapine. Am J Psychiatry 1993; 150:1561
  • Anderson ES, Power PS: Neuroleptic malignant syndrome as-sociated with clozapine use. J Clin Psychiatry 1991; 52:102–104
  • Muller 1 Becker 1 Fritze J: Neuroleptic malignant syndrome after clozapine plus carbamazepine. Lancet 1988; 2:1500
  • Nopoulos P, Flaum M, Miller DD: Atypical neuroleptic ma-lignant syndrome (NMS) with an atypical neuroleptic: Clozap-Me-induced NMS without rigidity. Ann Clin Psychiatry 1990; 2:251–253
  • Vetter p, Proppe D, Hoppe-Seyler S: Neuroleptic malignant syndrome with clozapine monotherapy and benign hyperther-mia after resolving neuroleptic malignant syndrome with clozapine. Two cases reports. Nervenarzt 1991; 62:55–57
  • Reddig S, Minnema AM, Tandon R: Neuroleptic malignant syndrome and clozapine. Ann Clin Psychiatry 1993; 5:25–27
  • Seeman P, Van Tot HHM: Dopamine receptor pharmacology. TIPS 1994; 15:264–268
  • Baldessarini RJ, Frakenburg FR: Clozapine: A novel antip-sychotic agent. N Engl J Med 1991; 324:746–754
  • Zito JM, Volavka J, Craig TJ, Czobor P, Baks S, Vitrai J: Pharmacoepidemiology of clozapine in 202 patients with schizophrenia. Ann Pharmacother 1993; 27:1262–1269
  • Kornhuber WM: Clozapine: A neuroleptic at risk of provok-ing neuroleptic malignant syndrome (NMS) or an alternative neuroleptic with positive NMS case history? Fortschr Neurol Psychiatr 1993; 61:217–222
  • Keck PE, McElroy SL, Pope HG: Epidemiology of neurolep-tic malignant syndrome. Psychiatry Ann 1991; 21:148–151
  • Addonizio G, Susma VL, Ruth SD: Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 1987; 22:1004–1020
  • Keck PE, Pope HG, Cohen BM: Rick factors for neuroleptic malignant syndrome. Arch Gen Psychiatry 1989; 46:914–918
  • Rosebush P, Stewart T: A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry 1991; 146:717–725

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.